标题
Therapeutic strategies for COVID-19: progress and lessons learned
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 22, Issue 6, Pages 449-475
出版商
Springer Science and Business Media LLC
发表日期
2023-04-19
DOI
10.1038/s41573-023-00672-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Early Treatment with Pegylated Interferon Lambda for Covid-19
- (2023) Gilmar Reis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 Entry
- (2022) Young‐Hee Shin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report
- (2022) Lisa K. Moores et al. CHEST
- Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study
- (2022) Aldo Marrone et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
- (2022) Mohammad Bosaeed et al. CLINICAL MICROBIOLOGY AND INFECTION
- A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
- (2022) Yi‐Chung Chang et al. EMBO Molecular Medicine
- How to Use and Interpret the Results of a Platform Trial
- (2022) Jay J. H. Park et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2022) Obbina Abani et al. LANCET
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2
- (2022) Avi J. Samelson et al. NATURE CELL BIOLOGY
- Innate immunity: the first line of defense against SARS-CoV-2
- (2022) Michael S. Diamond et al. NATURE IMMUNOLOGY
- A guide to immunotherapy for COVID-19
- (2022) Frank L. van de Veerdonk et al. NATURE MEDICINE
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid Diagnostic Testing for SARS-CoV-2
- (2022) Paul K. Drain NEW ENGLAND JOURNAL OF MEDICINE
- Targeting stem-loop 1 of the SARS-CoV-2 5′ UTR to suppress viral translation and Nsp1 evasion
- (2022) Setu M. Vora et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lethal mutagenesis as an antiviral strategy
- (2022) Ronald Swanstrom et al. SCIENCE
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
- (2022) Yueh-Ming Loo et al. Science Translational Medicine
- Convalescent plasma to deliver therapeutic antibodies against COVID-19
- (2022) Jonathon W. Senefeld et al. TRENDS IN MOLECULAR MEDICINE
- A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
- (2022) Ashleigh Shannon et al. Nature Communications
- Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19
- (2022) Andrea B. Troxel et al. JAMA Network Open
- Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates
- (2022) Quentin Le Hingrat et al. AIDS
- Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
- (2022) Gerard J. Criner et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19
- (2022) Tomas Cihlar et al. ANTIVIRAL THERAPY
- Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
- (2022) Yong-Qiang Deng et al. CELL RESEARCH
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
- (2022) Marisa Holubar et al. CLINICAL INFECTIOUS DISEASES
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
- (2022) Daniele Focosi et al. CLINICAL MICROBIOLOGY REVIEWS
- A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation
- (2022) Bonnie E. Lonze et al. CRITICAL CARE MEDICINE
- ADAM10 and ADAM17 promote SARS‐CoV‐2 cell entry and spike protein‐mediated lung cell fusion
- (2022) Georg Jocher et al. EMBO REPORTS
- Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
- (2022) Samantha E. Greasley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
- (2022) Yuto Unoh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues
- (2022) Rostom Ahmed-Belkacem et al. JOURNAL OF MEDICINAL CHEMISTRY
- Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
- (2022) Tika R. Malla et al. JOURNAL OF MEDICINAL CHEMISTRY
- Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
- (2022) Haozhou Tan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease
- (2022) Chamandi S. Dampalla et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anticoagulation in Patients With COVID-19
- (2022) Michael E. Farkouh et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
- (2022) Ryuta Uraki et al. NATURE
- Defining the risk of SARS-CoV-2 variants on immune protection
- (2022) Marciela M. DeGrace et al. NATURE
- Pan-coronavirus vaccine pipeline takes form
- (2022) Elie Dolgin NATURE REVIEWS DRUG DISCOVERY
- SARS-CoV-2 pathogenesis
- (2022) Mart M. Lamers et al. NATURE REVIEWS MICROBIOLOGY
- The immunology and immunopathology of COVID-19
- (2022) Miriam Merad et al. SCIENCE
- Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
- (2022) Alexandra Schäfer et al. Science Translational Medicine
- Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
- (2022) Daniel Ayoubkhani et al. BMJ-British Medical Journal
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
- (2022) Cameron R Wolfe et al. Lancet Respiratory Medicine
- Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study
- (2022) Gustavo Gomes Resende et al. Infectious Diseases
- Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
- (2022) ANNALS OF INTERNAL MEDICINE
- The Life of SARS-CoV-2 Inside Cells: Replication–Transcription Complex Assembly and Function
- (2022) Zhiyong Lou et al. Annual Review of Biochemistry
- Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial
- (2022) Anthony Raymond Tam et al. CLINICAL INFECTIOUS DISEASES
- Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
- (2022) Hao Zhou et al. CLINICAL MICROBIOLOGY REVIEWS
- Attenuation of SARS‐CoV ‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases
- (2022) Valter Bergant et al. EMBO JOURNAL
- Clinical grade ACE2 as a universal agent to block SARS‐CoV ‐2 variants
- (2022) Vanessa Monteil et al. EMBO Molecular Medicine
- Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candidate HN0037
- (2022) Christian Gege et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study
- (2022) Aranka V Ballering et al. LANCET
- Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
- (2022) Obbina Abani et al. LANCET
- From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
- (2022) Matthias Göhl et al. MOLECULES
- Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
- (2022) Qian Wang et al. NATURE
- Long-COVID treatments: why the world is still waiting
- (2022) Heidi Ledford NATURE
- Symptoms and risk factors for long COVID in non-hospitalized adults
- (2022) Anuradhaa Subramanian et al. NATURE MEDICINE
- Antibodies to combat viral infections: development strategies and progress
- (2022) Giuseppe Pantaleo et al. NATURE REVIEWS DRUG DISCOVERY
- Cell and Animal Models for SARS-CoV-2 Research
- (2022) Eloïne Bestion et al. Viruses-Basel
- Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2022) Stefano Barco et al. Lancet Haematology
- A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors
- (2022) Liming Yan et al. CELL
- The JAK-STAT pathway at 30: Much learned, much more to do
- (2022) Rachael L. Philips et al. CELL
- Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial
- (2022) Yoav Golan et al. CLINICAL INFECTIOUS DISEASES
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- (2022) Adarsh Bhimraj et al. CLINICAL INFECTIOUS DISEASES
- Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
- (2022) Terry Cheuk Fung Yip et al. CLINICAL INFECTIOUS DISEASES
- Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019 (COVID-19)
- (2022) John I Hogan et al. CLINICAL INFECTIOUS DISEASES
- Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021
- (2022) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants
- (2022) Frank P Esper et al. JOURNAL OF INFECTIOUS DISEASES
- Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
- (2022) Qiaoshuai Lan et al. JOURNAL OF MEDICAL VIROLOGY
- Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
- (2022) Norberto Perico et al. LANCET INFECTIOUS DISEASES
- Advances in covalent drug discovery
- (2022) Lydia Boike et al. NATURE REVIEWS DRUG DISCOVERY
- SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
- (2022) MacGregor Cox et al. NATURE REVIEWS MICROBIOLOGY
- Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
- (2022) Annaliesa S. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long covid—an update for primary care
- (2022) Trisha Greenhalgh et al. BMJ-British Medical Journal
- Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2022) Alexander P J Vlaar et al. Lancet Respiratory Medicine
- Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
- (2022) Hiroshi Mukae et al. CLINICAL INFECTIOUS DISEASES
- Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
- (2022) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
- (2022) Christopher C Butler et al. LANCET
- FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
- (2022) Teresa Brevini et al. NATURE
- Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
- (2022) Sho Iketani et al. NATURE
- VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
- (2022) Zhujun Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease
- (2022) Rukesh Chinthapatla et al. NUCLEIC ACIDS RESEARCH
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Coronavirus replication–transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit
- (2021) Heiko Slanina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
- (2021) Goran Kokic et al. Nature Communications
- Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics
- (2021) Monica C. Pillon et al. Nature Communications
- Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
- (2021) Amir Qaseem et al. ANNALS OF INTERNAL MEDICINE
- Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity
- (2021) Daisy A. Hoagland et al. IMMUNITY
- Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday
- (2021) Guangdi Li et al. MOLECULES
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Trends in peptide drug discovery
- (2021) Markus Muttenthaler et al. NATURE REVIEWS DRUG DISCOVERY
- Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin
- (2021) Wanchao Yin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
- (2021) Katerina Naydenova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
- (2021) Kris M. White et al. SCIENCE
- American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
- (2021) Adam Cuker et al. Blood Advances
- Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2
- (2021) Youngchang Kim et al. Communications Biology
- Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
- (2021) Philippe Karoyan et al. Communications Biology
- Antibody Response After SARS-CoV-2 Infection and Implications for Immunity
- (2021) Irina Arkhipova-Jenkins et al. ANNALS OF INTERNAL MEDICINE
- Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication
- (2021) Santseharay Ramirez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
- (2021) Jessica Sook Yuin Ho et al. CELL
- Antivirals with common targets against highly pathogenic viruses
- (2021) Lu Lu et al. CELL
- Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
- (2021) Luca Braga et al. NATURE
- Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
- (2021) Rita M. Meganck et al. NATURE MEDICINE
- Post-acute COVID-19 syndrome
- (2021) Ani Nalbandian et al. NATURE MEDICINE
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
- (2021) Kevin R. Bewley et al. Nature Protocols
- FDA approves 100th monoclonal antibody product
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity
- (2021) Sheng Lin et al. NUCLEIC ACIDS RESEARCH
- Anticoagulation in COVID-19: current concepts and controversies
- (2021) Atanu Chandra et al. POSTGRADUATE MEDICAL JOURNAL
- The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
- (2021) Jasmine Cubuk et al. Nature Communications
- The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
- (2021) Manon Laporte et al. PLoS Pathogens
- How COVID-19 has fundamentally changed clinical research in global health
- (2021) Jay J H Park et al. Lancet Global Health
- Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
- (2021) Sanjay Ramakrishnan et al. Lancet Respiratory Medicine
- The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
- (2021) Thomas P. Peacock et al. Nature Microbiology
- Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
- (2021) Jiashu Xie et al. Acta Pharmaceutica Sinica B
- SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation
- (2021) Bingyu Yan et al. Science Immunology
- The origins of SARS-CoV-2: A critical review
- (2021) Edward C. Holmes et al. CELL
- Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
- (2021) Liming Yan et al. CELL
- Long-term differentiating primary human airway epithelial cell cultures: how far are we?
- (2021) Zuzanna Bukowy-Bieryłło Cell Communication and Signaling
- Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19
- (2021) Jintanat Ananworanich et al. CLINICAL INFECTIOUS DISEASES
- SARS-CoV-2 Antiviral Therapy
- (2021) Kaiming Tao et al. CLINICAL MICROBIOLOGY REVIEWS
- TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
- (2021) Jana Koch et al. EMBO JOURNAL
- Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
- (2021) Roberto Caricchio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies
- (2021) Arun K. Ghosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- (2021) Ly-Mee Yu et al. LANCET
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- (2021) Florence Ader et al. LANCET INFECTIOUS DISEASES
- Targeting liquid–liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity
- (2021) Shuai Wang et al. NATURE CELL BIOLOGY
- The current landscape of nucleic acid therapeutics
- (2021) Jayesh A. Kulkarni et al. Nature Nanotechnology
- mRNA vaccines for infectious diseases: principles, delivery and clinical translation
- (2021) Namit Chaudhary et al. NATURE REVIEWS DRUG DISCOVERY
- Structural biology of SARS-CoV-2 and implications for therapeutic development
- (2021) Haitao Yang et al. NATURE REVIEWS MICROBIOLOGY
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- (2021) Florian Kabinger et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme
- (2021) Chang Liu et al. SCIENCE
- Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
- (2021) Tia A. Tummino et al. SCIENCE
- Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
- (2021) C. Glenn Begley et al. Science Translational Medicine
- The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
- (2021) Kun Li et al. mBio
- Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate
- (2021) Olga Bobiļeva et al. ACS Medicinal Chemistry Letters
- Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
- (2021) Haixia Su et al. Nature Communications
- Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
- (2021) Joseph A. Newman et al. Nature Communications
- Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
- (2021) Kangsa Amporndanai et al. Nature Communications
- A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2′-O methylation of its first nucleotide
- (2021) Thiruselvam Viswanathan et al. Nature Communications
- Long covid—mechanisms, risk factors, and management
- (2021) Harry Crook et al. BMJ-British Medical Journal
- Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2
- (2021) Abhisek Dwivedy et al. PLoS Computational Biology
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- Cellular host factors for SARS-CoV-2 infection
- (2021) Jim Baggen et al. Nature Microbiology
- Cell therapy strategies for COVID-19: Current approaches and potential applications
- (2021) Mark M. Zaki et al. Science Advances
- Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection
- (2021) Michael J. Christie et al. Science Immunology
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
- (2021) et al. ANNALS OF INTERNAL MEDICINE
- 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
- (2021) Alessia Alunno et al. ANNALS OF THE RHEUMATIC DISEASES
- 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors
- (2021) Jianyuan Zhao et al. ANTIVIRAL RESEARCH
- Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
- (2021) Jean M. Connors et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Perspectives on SARS-CoV-2 Main Protease Inhibitors
- (2021) Kaifu Gao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity
- (2021) Zhengnan Shen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Diagnostics for COVID-19: moving from pandemic response to control
- (2021) Rosanna W Peeling et al. LANCET
- Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
- (2021) Eduardo Ramacciotti et al. LANCET
- The emergence, genomic diversity and global spread of SARS-CoV-2
- (2021) Juan Li et al. NATURE
- Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19
- (2021) Sarthak Sinha et al. NATURE MEDICINE
- Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design
- (2021) Brandon Malone et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mechanisms of SARS-CoV-2 entry into cells
- (2021) Cody B. Jackson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronaviral RNA-methyltransferases: function, structure and inhibition
- (2021) Radim Nencka et al. NUCLEIC ACIDS RESEARCH
- The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme
- (2021) Alexander P Walker et al. NUCLEIC ACIDS RESEARCH
- Characterization of the SARS-CoV-2 ExoN (nsp14ExoN–nsp10) complex: implications for its role in viral genome stability and inhibitor identification
- (2021) Hannah T Baddock et al. NUCLEIC ACIDS RESEARCH
- Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
- (2021) Shubhankar Ambike et al. NUCLEIC ACIDS RESEARCH
- Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition
- (2021) Xiaolei Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
- (2021) Nicole Ezer et al. BMJ-British Medical Journal
- Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
- (2021) Yao Zhao et al. Protein & Cell
- Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19
- (2021) Brian M. Clemency et al. JAMA Internal Medicine
- Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
- (2021) Benjamin A Fisher et al. Lancet Respiratory Medicine
- Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
- (2021) Andre C Kalil et al. Lancet Respiratory Medicine
- Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
- (2021) Zelalem Temesgen et al. Lancet Respiratory Medicine
- Approved HIV reverse transcriptase inhibitors in the past decade
- (2021) Guangdi Li et al. Acta Pharmaceutica Sinica B
- Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties
- (2021) Ryan P. Bennett et al. JCI Insight
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
- (2020) Shuai Xia et al. Cellular & Molecular Immunology
- Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases
- (2020) Rowan S. Hardy et al. Nature Reviews Rheumatology
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Advances in therapeutic peptides targeting G protein-coupled receptors
- (2020) Anthony P. Davenport et al. NATURE REVIEWS DRUG DISCOVERY
- Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV ‐2
- (2020) Youngchang Kim et al. PROTEIN SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex
- (2020) James Chen et al. CELL
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
- (2020) Massimo Tempestilli et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
- (2020) Julien Carvelli et al. NATURE
- Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
- (2020) Donghyuk Shin et al. NATURE
- Extrapulmonary manifestations of COVID-19
- (2020) Aakriti Gupta et al. NATURE MEDICINE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
- (2020) Zachary A. Gurard-Levin et al. ANTIVIRAL RESEARCH
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor
- (2020) Peng Zhao et al. Cell Host & Microbe
- Remdesivir against COVID-19 and Other Viral Diseases
- (2020) Jakob J. Malin et al. CLINICAL MICROBIOLOGY REVIEWS
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
- (2020) Wioletta Rut et al. Nature Chemical Biology
- COVID-19 clinical trials: learning from exceptions in the research chaos
- (2020) Kari A. O. Tikkinen et al. NATURE MEDICINE
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
- (2020) Suzanne J. F. Kaptein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
- (2020) Ashleigh Shannon et al. Nature Communications
- Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
- (2020) Ya-Wen Cheng et al. Cell Reports
- Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
- (2020) Daniel E Leisman et al. Lancet Respiratory Medicine
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design
- (2020) Wioletta Rut et al. Science Advances
- Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
- (2020) Jingwei Bian et al. Acta Pharmaceutica Sinica B
- Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis
- (2020) Liming Yan et al. CELL
- Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains
- (2020) Tongqing Zhou et al. Cell Host & Microbe
- An organoid‐derived bronchioalveolar model for SARS‐CoV‐2 infection of human alveolar type II‐like cells
- (2020) Mart M Lamers et al. EMBO JOURNAL
- Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
- (2020) Sean X. Gu et al. Nature Reviews Cardiology
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
- (2020) Michael A Matthay et al. Lancet Respiratory Medicine
- Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins
- (2020) Flavia Squeglia et al. Frontiers in Chemistry
- Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment
- (2019) Eva Vidak et al. Cells
- Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
- (2019) Kevin O. Saunders Frontiers in Immunology
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
- (2019) Ariane J. Brown et al. ANTIVIRAL RESEARCH
- The increasing impact of lethal mutagenesis of viruses
- (2019) Celia Perales et al. Future Medicinal Chemistry
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- 100 Years of Suramin
- (2019) Natalie Wiedemar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
- (2018) Eva Lhuissier et al. Oncotarget
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
- (2017) Dustin Siegel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Host-directed therapies for bacterial and viral infections
- (2017) Stefan H. E. Kaufmann et al. NATURE REVIEWS DRUG DISCOVERY
- Deubiquitylating enzymes and drug discovery: emerging opportunities
- (2017) Jeanine A. Harrigan et al. NATURE REVIEWS DRUG DISCOVERY
- Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
- (2017) François Ferron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
- (2016) Arun K. Ghosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Accessory proteins of SARS-CoV and other coronaviruses
- (2014) Ding Xiang Liu et al. ANTIVIRAL RESEARCH
- Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
- (2014) Lu Lu et al. Nature Communications
- Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides
- (2012) Aesop Cho et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
- (2009) Yousuke Furuta et al. ANTIVIRAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started